NCT Number: NCT00356564
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Persistence of seroprotective antibody concentrations & immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
Looking for future studies?
Notify MeKey information
Conditions
Age range
7 year–9 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
GSK Investigational Site, Ettenheim, Baden-Wurttemberg, Germany
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- A male or female aged 7 to 9 years at the time of study entry .
- Subjects who have received a total of 4 doses of DTPa-HBV-IPV/Hib vaccine or a total of 4 doses of HBV vaccine in previous vaccination studies.
- Evidence of previous hepatitis B booster vaccination or disease since administration of the fourth dose of DTPa-HBV-IPV/Hib or HBV vaccine.
Treatment and study plan
Primary outcomes
-
Anti-HBs antibody concentration
Secondary outcomes
-
Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.
-
Sol & unsol symptoms after HBV vaccination, SAEs
Sponsors and collaborators
Lead sponsor
GlaxoSmithKline
Industry
Registry information
Official study title
Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B and Immune Response to a Hepatitis B Challenge Dose in Healthy Children 7 to 9 Years Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine
Important dates
- Study start
- 2006
- Study completion
- 2006
- First posted
- Jul 26, 2006
- Registry last updated
- Oct 12, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
NCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsStudy to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
NCT06422767
Blood-Borne Infections, Communicable Diseases
Austin, Texas, United States
View Trial DetailsA Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
NCT07637214
Blood-Borne Infections, Bronchial Diseases
Wuhan, Hubei, China
View Trial DetailsStudy of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
NCT05551273
Blood-Borne Infections, Communicable Diseases
San Diego, California, United States
View Trial Details